A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: A comparison with existing approaches

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Khan, Iftekhar ^a   Morris, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cross walking; EORTC QLQ C30; Health economics; Lung cancer; Mapping; Quality of life

Indexed keywords

ERLOTINIB; PLACEBO;

ADULT; AGED; ARTICLE; BETA BINOMIAL REGRESSION MODEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; EURO QUALITY OF LIFE 5D 3L SCORE; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NON SMALL CELL LUNG CANCER; NONLINEAR SYSTEM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; QLQ C30 SCORE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ALGORITHM; EVALUATION STUDY; FEMALE; HEALTH STATUS; LUNG TUMOR; MALE; PSYCHOLOGY; QUESTIONNAIRE; REGRESSION ANALYSIS; REPRODUCIBILITY; STANDARDS; STATISTICAL MODEL; VALIDATION STUDY;

ADULT; ALGORITHMS; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES;

EID: 84920832869     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-014-0163-7     Document Type: Article

References (45)

1. Guide to the methods of technology appraisals. [website]: NICE; 2004 [cited 2012 1st October]; Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/GuideToMethodsTA201112.jsp.
2. Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35(11):1095-1108 [Research Support, Non-U.S. Gov't].
3. Drummond MA: Economic Evaluation in Health Care, Merging theory with practice; 2001.
4. Dunlop W, Uhl R, Khan I, Taylor A, Barton G: Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012, 15(3):564-575 [Research Support, Non-U.S. Gov't].
5. Crott R, Versteegh M, Uyl-de-Groot C: An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Qual Life Res 2013, 22(5):1045-1054. doi:10.1007/s11136-012-0220-9. Epub 2012 Jun 29.
6. Brazier JE, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010, 11(2):215-225 [Research Support, Non-U.S. Gov't Review].
7. Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR: Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Out 2008, 14:6.
8. Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A: A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl Health Econ Health Policy 2013, 11(1):27-43. doi:10.1007/s40258-012-0001-1.
9. Longworth L, Rowen D: Value Health 2013, 16(1):202-210.
10. Scuffham PA, Whitty JA, Mitchell A, Viney R: The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4. Pharmacoeconomics 2008, 26(4):297-310.
11. CHMP: Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis; 2005.
12. Rowen D, Brazier J, Young T, Gaugris S, Craig BM, King MT, Velikova G: Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011, 14(5):721-731. doi:10.1016/j.jval.2011.01.004.
13. Round J: Capturing Information Loss in Estimates of Uncertainty That Arise from Mapping Algorithms.: Health Economists' Study Group; 2008.
14. Chuang LH, Whitehead SJ: Mapping for economic evaluation. Br Med Bull 2012, 101:1-15.
15. Crott R, Briggs A: Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ 2010, 11(4):427-434.
16. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl NB: Derivation of utility values from EORTC QLQ-C30 values in lung cancer. J Thorac Oncol 2009, 4(9):S420-S421.
17. Kim EJ, Ko SK, Kang HY: Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res 2012, 21(7):1193-1203 [Research Support, Non-U.S. Gov't].
18. Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009, 12(8):1151-1157.
19. McKenzie L, van der Pol M: Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health 2009, 12(1):167-171.
20. Kharroubi SA, Brazier JE, Roberts J, O'Hagan A: Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 2007, 26(3):597-612.
21. Gray AM, Rivero-Arias O, Clarke PM: Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006, 26(1):18-29.
22. Hernández Alava M, Wailoo AJ, Ara R: Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health 2012, 15(3):550-561.
23. Basu A, Manca A: Regression estimators for generic health-related quality of life and quality-adjusted life years. Med Decis Making 2012, 32(1):56-69.
24. Le QA, Doctor JN: Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Med Care 2011, 49(5):451-460.
25. Versteegh MM, Rowen D, Brazier JE, Stolk EA: Mapping onto EQ-5D for patients in poor health. Health Qual Life Out 2010, 8:141.
26. Paolino P: Maximum likelihood Estimation of models with beta-distributed dependent variables. Polit Anal 2001, 9(4):325-346.
27. EORTC Quality of life. EORTC: [cited 2012 10th October]; Available from: http://groups.eortc.be/qol/eortc-qlq-c30.
28. Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012, 13(11):1161-1170. doi:10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.
29. Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer. 2014 Oct 7. doi:10.1016/j.ejca.2014.07.009
30. Honore B, Khan S, Powell JL: Quantile regression under random censoring. J Econometrics 2002, 109(1):67-105.
31. Koenker R: Quantile Regression (Econometric Society Monographs); 2005.
32. Khan S, Powell JL: Two-step estimation of semiparametric censored regression models. J Econometrics 2001, 103(1-2):73-110.
33. Powell JL: Least absolute deviations estimation for the censored regression-model. J Econometrics 1984, 25(3):303-325.
34. Kaambwa B, Billingham L, Bryan S: Mapping utility scores from the Barthel index. Eur J Health Econ 2013, 14(2):231-241. doi:10.1007/s10198-011-0364-5. Epub 2011 Nov 2.
35. Willan AR: Statistical analysis of cost-effectiveness data from randomized clinical trials. Expert Rev Pharmacoecon Outcomes Res 2006, 6(3):337-346.
36. Willan AR: Sample size determination for cost-effectiveness trials. Pharmacoeconomics 2011, 29(11):933-949.
37. Briggs AH, Claxton K, Sculpher MJ: Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
38. Ospina R, Ferrari SLP, Cribari-Neto F: A general class of zero-or-one inflated beta regression models. Comp Stat Data Analysis 2004, 31(7):799-815.
39. Kieschnick R, McCullough BD: Regression analysis of variates observed on (0,1): percentages, proportions and fractions. Stat Model 2003, 3(3):193-213.
40. Swearingen CJ, Castro MSM, Bursac Z: Inflated Beta Regression: Zero, one and Everything in Between, SAS Global Forum; 2012.
41. Ospina R, Ferrari SLP: A general class of zero-or-one inflated beta regression models. Comput Stat Data Anal 2012, 56:1609-1623.
42. Ferrari SLP, Cribari-Neto F: Beta regression for modelling rates and proportions. J Appl Stat 2004, 31(7):799-815.
43. Fleishman AI: A method of simulating non-normal distributions. Psychometrika 1978, 43:521-531.
44. Pourahmadi M, Daniels MJ, Park T: Simultaneous modelling of the Cholesky decomposition of several covariance matrices. J Multivariate Anal 2007, 98(3):568-587.
45. Kind P: Measuring the value of quality of life in cancer: an index based on EORTC QLQ-C30 presentation (abstract), ASCO 2005 Annual Meeting. J Clin Oncol 2005, 29(16S, Part I and II).